Compare Stocks: CDTX, INSM, UTHR, and INCY

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CDTX Cidara Therapeutics	$221.38 +0.0%	$220.96	$18.51 ▼ $221.42	$6.96B	1.52	928,762 shs	2.69 million shs
INCY Incyte	$122.27 +1.6%	$119.46	$89.25 ▼ $132.60	$24.92B	0.78	1.74 million shs	1.19 million shs
INSM Insmed	$120.75 +1.1%	$111.12	$90.39 ▼ $212.75	$26.49B	0.83	3.02 million shs	1.49 million shs
UTHR United Therapeutics	$595.66 +1.2%	$536.90	$452.44 ▼ $614.23	$25.37B	0.49	555,869 shs	369,674 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CDTX Cidara Therapeutics	0.00%	0.00%	0.00%	0.00%	+113.30%
INCY Incyte	-1.30%	+2.30%	+6.66%	-0.39%	+13.51%
INSM Insmed	+2.92%	+14.41%	+18.78%	-9.67%	-37.74%
UTHR United Therapeutics	+1.06%	-2.11%	+7.18%	+15.03%	+29.67%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CDTX Cidara Therapeutics	$221.38 +0.0%	$220.96	$18.51 ▼ $221.42	$6.96B	1.52	928,762 shs	2.69 million shs
INCY Incyte	$122.27 +1.6%	$119.46	$89.25 ▼ $132.60	$24.92B	0.78	1.74 million shs	1.19 million shs
INSM Insmed	$120.75 +1.1%	$111.12	$90.39 ▼ $212.75	$26.49B	0.83	3.02 million shs	1.49 million shs
UTHR United Therapeutics	$595.66 +1.2%	$536.90	$452.44 ▼ $614.23	$25.37B	0.49	555,869 shs	369,674 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CDTX Cidara Therapeutics	0.00%	0.00%	0.00%	0.00%	+113.30%
INCY Incyte	-1.30%	+2.30%	+6.66%	-0.39%	+13.51%
INSM Insmed	+2.92%	+14.41%	+18.78%	-9.67%	-37.74%
UTHR United Therapeutics	+1.06%	-2.11%	+7.18%	+15.03%	+29.67%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CDTX Cidara Therapeutics	2.00	Hold	N/A	N/A
INCY Incyte	2.40	Hold	$132.86	8.66% Upside
INSM Insmed	2.92	Moderate Buy	$196.52	62.75% Upside
UTHR United Therapeutics	2.69	Moderate Buy	$676.40	13.55% Upside

Current Analyst Ratings Breakdown

Latest CDTX, INSM, UTHR, and INCY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
11/9/2026	UTHR United Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Buy (B-) ➝ Hold (C+)
11/9/2026	UTHR United Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$660.00
11/5/2026	UTHR United Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$700.00 ➝ $703.00
11/5/2026	INCY Incyte	Leerink Partners Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Outperform	$154.00 ➝ $150.00
11/5/2026	UTHR United Therapeutics	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$675.00 ➝ $700.00
11/5/2026	UTHR United Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Outperform	$697.00 ➝ $725.00
11/4/2026	INCY Incyte	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Buy (B) ➝ Hold (C)
11/4/2026	UTHR United Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$720.00
11/4/2026	INSM Insmed	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$220.00
11/4/2026	UTHR United Therapeutics	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$728.00 ➝ $768.00
11/2/2026	INSM Insmed	Benchmark Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy

(Data available from 11/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CDTX Cidara Therapeutics	N/A	N/A	N/A	N/A	$14.92 per share	N/A
INCY Incyte	$5.14B	4.85	$6.20 per share	19.72	$27.68 per share	4.42
INSM Insmed	$606.42M	43.68	N/A	N/A	$3.31 per share	36.48
UTHR United Therapeutics	$3.19B	7.96	$33.73 per share	17.66	$147.36 per share	4.04

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CDTX Cidara Therapeutics	-$169.83M	-$11.78	N/A	N/A	N/A	N/A	-45.52%	-38.31%	N/A
INCY Incyte	$1.29B	$1.88	65.04	15.40	4.44	6.71%	7.92%	6.12%	N/A
INSM Insmed	-$1.28B	-$2.82	N/A	194.76	N/A	-39.85%	-96.38%	-32.55%	N/A
UTHR United Therapeutics	$1.33B	$26.50	22.48	18.59	3.97	38.61%	19.18%	17.07%	N/A

Latest CDTX, INSM, UTHR, and INCY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/4/2026	Q3 2026	UTHR United Therapeutics	$6.01	$5.71	-$0.30	$5.71	$781.14 million	$832.50 million
10/29/2026	Q3 2026	INCY Incyte	-$3.93	-$3.60	+$0.33	-$3.86	$1.46 billion	$1.56 billion
10/29/2026	Q3 2026	INSM Insmed	-$0.3827	-$0.46	-$0.0773	-$0.46	$500.36 million	$524.43 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CDTX Cidara Therapeutics	N/A	N/A	N/A	N/A	N/A
INCY Incyte	N/A	N/A	N/A	N/A	N/A
INSM Insmed	N/A	N/A	N/A	N/A	N/A
UTHR United Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CDTX Cidara Therapeutics	N/A	4.62	4.62
INCY Incyte	N/A	3.84	3.75
INSM Insmed	0.77	2.86	2.59
UTHR United Therapeutics	N/A	4.61	4.29

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CDTX Cidara Therapeutics	35.82%
INCY Incyte	96.97%
INSM Insmed	N/A
UTHR United Therapeutics	94.08%

Insider Ownership

Company	Insider Ownership
CDTX Cidara Therapeutics	3.89%
INCY Incyte	16.20%
INSM Insmed	2.10%
UTHR United Therapeutics	8.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CDTX Cidara Therapeutics	90	31.44 million	30.22 million	No Data
INCY Incyte	2,844	203.83 million	170.81 million	Optionable
INSM Insmed	1,664	219.38 million	214.77 million	Optionable
UTHR United Therapeutics	1,400	42.59 million	38.93 million	Optionable

CDTX, INSM, UTHR, and INCY Headlines

Recent News About These Companies

Analysts Issue Forecasts for UTHR FY2026 Earnings

November 11 at 7:11 AM | marketbeat.com

United Therapeutics (NASDAQ:UTHR) Director Sells $701,800.00 in Stock

November 11 at 5:22 AM | insidertrades.com

HC Wainwright Initiates Coverage on United Therapeutics (NASDAQ:UTHR)

November 11 at 1:31 AM | americanbankingnews.com

United Therapeutics (NASDAQ:UTHR) Stock: Insider Christopher Patusky Sells 1,210 Shares

November 10 at 5:07 PM | marketbeat.com

United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 7,886 Shares of Stock

November 10 at 5:07 PM | marketbeat.com

United Therapeutics (NASDAQ:UTHR) CEO Sells $5,362,845.00 in Stock

November 10 at 4:07 AM | insidertrades.com

Critical Comparison: United Therapeutics (NASDAQ:UTHR) vs. Black Diamond Therapeutics (NASDAQ:BDTX)

November 10 at 2:15 AM | americanbankingnews.com

Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares of Stock

November 9 at 7:07 PM | marketbeat.com

United Therapeutics Corporation Announces Participation at Upcoming November 2026 Investor Conferences

November 9 at 12:01 PM | biospace.comB

United Therapeutics Corporation Announces Participation at Upcoming Investor Conferences

November 9 at 12:01 PM | aol.comA

United Therapeutics (NASDAQ:UTHR) Now Covered by HC Wainwright

November 9 at 8:17 AM | marketbeat.com

4,954 United Therapeutics Corporation $UTHR Shares Acquired by University of Texas Texas AM Investment Management Co.

November 9 at 6:19 AM | marketbeat.com

12,583 Shares of United Therapeutics Corporation $UTHR Acquired by Hohimer Wealth Management LLC

November 9 at 6:11 AM | marketbeat.com

United Therapeutics Corporation $UTHR Stock Holdings Reduced by Pictet Asset Management Holding SA

November 9 at 5:39 AM | marketbeat.com

3,010 Shares of United Therapeutics Corporation $UTHR Purchased by Mirae Asset Global Investments Co. Ltd.

November 8 at 5:00 AM | marketbeat.com

Insider Selling: United Therapeutics (NASDAQ:UTHR) EVP Sells $4,968,961.00 in Stock

November 8 at 4:09 AM | americanbankingnews.com

United Therapeutics Insider Sold Shares Worth $1,171,609, According to a Recent SEC Filing

November 6, 2026 | marketscreener.comM

United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 7,540 Shares of Stock

November 6, 2026 | marketbeat.com

The 5 most interesting analyst questions from United Therapeutics’s Q3 2026 earnings call

November 6, 2026 | msn.com

United Therapeutics (NASDAQ:UTHR) Stock Price Expected to Rise, BTIG Research Analyst Says

November 6, 2026 | americanbankingnews.com

United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 7,777 Shares of Company Stock

November 5, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDTX, INSM, UTHR, and INCY Company Descriptions

Cidara Therapeutics NASDAQ:CDTX

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

Incyte NASDAQ:INCY

$122.27 +1.97 (+1.64%)

Closing price 04:00 PM Eastern

Extended Trading

$120.06 -2.21 (-1.80%)

As of 07:05 PM Eastern

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Insmed NASDAQ:INSM

$120.75 +1.26 (+1.05%)

Closing price 04:00 PM Eastern

Extended Trading

$119.20 -1.55 (-1.28%)

As of 07:12 PM Eastern

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

United Therapeutics NASDAQ:UTHR

$595.66 +7.05 (+1.20%)

Closing price 04:00 PM Eastern

Extended Trading

$597.49 +1.83 (+0.31%)

As of 05:40 PM Eastern

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CDTX, INSM, UTHR, and INCY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CDTX, INSM, UTHR, and INCY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CDTX, INSM, UTHR, and INCY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDTX, INSM, UTHR, and INCY Company Descriptions

Cidara Therapeutics NASDAQ:CDTX

Incyte NASDAQ:INCY

Insmed NASDAQ:INSM

United Therapeutics NASDAQ:UTHR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CDTX, INSM, UTHR, and INCY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CDTX, INSM, UTHR, and INCY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CDTX, INSM, UTHR, and INCY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDTX, INSM, UTHR, and INCY Company Descriptions

Cidara Therapeutics NASDAQ:CDTX

Incyte NASDAQ:INCY

Insmed NASDAQ:INSM

United Therapeutics NASDAQ:UTHR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools